awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q33938441-6F7A685C-34F3-49B8-8768-CF3A0447E9B0
Q33938441-6F7A685C-34F3-49B8-8768-CF3A0447E9B0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33938441-6F7A685C-34F3-49B8-8768-CF3A0447E9B0
Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer.
P2860
Q33938441-6F7A685C-34F3-49B8-8768-CF3A0447E9B0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33938441-6F7A685C-34F3-49B8-8768-CF3A0447E9B0
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
ee4ebdebd16c57f9513f5da31a262fe45d74b213
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.